Objective:
To investigate if a pronounced ciliary muscle contraction, induced by physostigmine salicylate, can abolish the ocular hypotensive effect of latanoprost, a prostaglandin analogue, via inhibition of the uveoscleral outflow.
Design:
A randomized, crossover study that was double-masked for latanoprost. Physostigmine was the second factor in a 22 factorial experiment.
Participants:
A total of 20 male and female healthy volunteers (median age, 25 years; age range, 17-30 years).
Interventions:
Between 7 am and 7 pm, 1 drop of physostigmine salicylate (8 mg/mL) was instilled in 1 eye every other hour. At 8 am, 1 drop of either latanoprost (50 mg/L or placebo was instilled in both eyes. This protocol was repeated a second time with latanoprost administered to previously placebo-treated eyes and vice versa.
Main Outcome Measures:
Intraocular pressure differences were measured with Goldmann applanation tonometry hourly for 13 hours.
Results:
Latanoprost reduced the intraocular pressure significantly at 3 to 12 hours after application with a maximal effect at 8 hours after the administration of the dose. The reduction that was obtained with physostigmine administered every other hour was more pronounced, was observed at 1 hour after the administration of the first dose, and increased throughout the day. A significant interaction was seen between 3 and 6 PM (ie, at 7-10 hours after application of latanoprost).
Conclusions:
Latanoprost and physostigmine have a mainly additive ocular hypotensive effect. Thus, high doses of physostigmine did not abolish the eye pressure-lowering effect of latanoprost, but some interaction was seen at low intraocular pressures. It was concluded that any mechanical effect on the uveoscleral flow achieved with physostigmine is short-lasting compared with the effect obtained with latanoprost, and that latanoprost and miotics can be combined.